Researchers from Brigham and Women's Hospital (BWH) and Dana-Farber
Cancer Institute (DFCI) have received a $10 million Breakthrough Award
from the Department of Defense's Office of the Congressional Directed
Medical Research Program to test whether aspirin helps women with breast
cancer avoid recurrence and live longer. This is the first ever
randomized trial in the United States testing aspirin in the disease,
which impacts more than 3 million American women who are living with a
breast cancer diagnosis.
The Aspirin for Breast Cancer (ABC) Trial will recruit 3,000
women with Stages II and III breast cancer through The Alliance for
Clinical Trials in Oncology (Alliance) which is a national clinical
trials network sponsored by the National Cancer Institute (NCI)
headquartered at Brigham and Women's Hospital. Half of the women
participating in the trial will be randomly assigned to receive aspirin
and half to receive a placebo pill.
Previous observational research, where scientists observe
peoples' behavior, and correlate that behavior with their health, has
found that breast cancer survivors who were regular aspirin users had a
50 percent lower risk of breast cancer recurrence and death compared to
those who did not use aspirin.
No comments:
Post a Comment